Cargando…

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data

OBJECTIVES: To describe and compare the occurrence of newly diagnosed uveitis in children with JIA receiving MTX, etanercept, adalimumab and infliximab. METHODS: This on-drug analysis included patients within UK JIA registries (British Society for Paediatric and Adolescent Rheumatology Etanercept Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Rebecca, De Cock, Diederik, Kearsley-Fleet, Lianne, Southwood, Taunton, Baildam, Eileen, Beresford, Michael W, Foster, Helen E, Thomson, Wendy, Ramanan, Athimalaipet V, Hyrich, Kimme L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244776/ https://www.ncbi.nlm.nih.gov/pubmed/31605484 http://dx.doi.org/10.1093/rheumatology/kez449

Ejemplares similares

P66 Adalimumab originator versus biosimilar in children and young people with JIA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
por: Davies, Rebecca, et al.
Publicado: (2014)

Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2020)

Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Treatment prescribing patterns in a cohort of patients with juvenile idiopathic arthritis (JIA). Data from the childhood arthritis prospective study (CAPS)
por: Davies, Rebecca, et al.
Publicado: (2014)

Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS)
por: McErlane, Flora, et al.
Publicado: (2018)

Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS)()()
por: Davies, Rebecca, et al.
Publicado: (2016)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

How common is remission in juvenile idiopathic arthritis: A systematic review
por: Shoop-Worrall, Stephanie J.W., et al.
Publicado: (2017)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

OA35 Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
por: Costello, Ruth, et al.
Publicado: (2022)

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2018)

P57 What are the outcomes of persistent oligoarthritis? A systematic review plan
por: Smith, Andrew, et al.
Publicado: (2022)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Evaluation of an nhs juvenile idiopathic arthritis (JIA) treatment pathway compared to published international recommendations
por: Green, Katherone L, et al.
Publicado: (2014)

Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
por: Costello, Ruth E, et al.
Publicado: (2022)

Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?
por: Ramanan, Athimalaipet V., et al.
Publicado: (2022)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Juvenile Idiopathic Arthritis Associated Uveitis
por: Carlsson, Emil, et al.
Publicado: (2021)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

The prioritization of symptom beliefs over illness beliefs: The development and validation of the Pain Perception Questionnaire for Young People
por: Ghio, Daniela, et al.
Publicado: (2017)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Intra-articular corticosteroid injections in juvenile idiopathic arthritis
por: Carrasco, Roberto, et al.
Publicado: (2014)

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
por: Kihara, Mari, et al.
Publicado: (2016)

No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA
por: Yarwood, Annie, et al.
Publicado: (2022)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen M, et al.
Publicado: (2019)

Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis
por: Hyrich, Kimme L, et al.
Publicado: (2016)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
por: Lawson-Tovey, Saskia, et al.
Publicado: (2023)

Juvenile idiopathic arthritis-associated uveitis
por: Clarke, Sarah L. N., et al.
Publicado: (2016)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rvbiukajjr0bqt8mlllv4d3avv